November 27, 2019
M&A activity soars as life sciences see dealmaking core to growth strategy
Following a modest 2018, life sciences M&A has roared to life in 2019, exceeding the US$300 billion mark year to date. If this pace continues, the industry is on track to experience its best dealmaking year since EY began surveying M&A activity 10 years ago. An EY article explains.